Cargando…
Hämoadsorption zur Blutreinigung – Unvergleichbarkeit der klinisch angebotenen Verfahren
BACKGROUND: In the field of intensive care medicine, but also increasingly in cardiac surgery, the use of adsorptive blood purification technologies for the treatment of hyperinflammatory conditions is becoming progressively more important. In addition to the CytoSorb concept, which is more and more...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Medizin
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8159789/ https://www.ncbi.nlm.nih.gov/pubmed/32583037 http://dx.doi.org/10.1007/s00063-020-00702-2 |
_version_ | 1783700158140121088 |
---|---|
author | Krenn, C. G. Steltzer, H. |
author_facet | Krenn, C. G. Steltzer, H. |
author_sort | Krenn, C. G. |
collection | PubMed |
description | BACKGROUND: In the field of intensive care medicine, but also increasingly in cardiac surgery, the use of adsorptive blood purification technologies for the treatment of hyperinflammatory conditions is becoming progressively more important. In addition to the CytoSorb concept, which is more and more clinically accepted and currently the most frequently used method, other companies—particularly from China—have recently entered the market with similar concepts. OBJECTIVES: Given this, the aim of this article is to analyze the different aspects of the various hemoadsorption products offered on the market today and to take a critical look at the available evidence. METHODS: Technical features, application-specific characteristics, and the existing evidence of the adsorption technologies CytoSorb® (CytoSorbents(TM) Inc., Monmouth Junction, NJ, USA), Jafron® HA series (Jafron Biomedical Co., Guangdong, China), and Biosky® MG series (Biosun® Medical Technology Co., Foshan City, Guangdong Province, China) were analyzed. The purely substance-specific methods for endotoxin elimination only (Toraymyxin®, Alteco®) were not considered. RESULTS: A comprehensive analysis of these criteria reveals that there are considerable differences between the various available technologies in terms of materials used, adsorption characteristics, application, and available data on safety and clinical experience. Furthermore, it becomes clear that not only the efficacy of blood purification technologies should be considered in terms of an effect–price–performance ratio, but that in particular the safety of the individual technologies is of crucial importance. DISCUSSION: Among the technologies analyzed, CytoSorb currently represents the most investigated and clinically established procedure. Furthermore, it should be noted that clinical results, but particularly safety-relevant aspects, are not transferable between the products due to technically different procedures. |
format | Online Article Text |
id | pubmed-8159789 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer Medizin |
record_format | MEDLINE/PubMed |
spelling | pubmed-81597892021-06-01 Hämoadsorption zur Blutreinigung – Unvergleichbarkeit der klinisch angebotenen Verfahren Krenn, C. G. Steltzer, H. Med Klin Intensivmed Notfmed Übersichten BACKGROUND: In the field of intensive care medicine, but also increasingly in cardiac surgery, the use of adsorptive blood purification technologies for the treatment of hyperinflammatory conditions is becoming progressively more important. In addition to the CytoSorb concept, which is more and more clinically accepted and currently the most frequently used method, other companies—particularly from China—have recently entered the market with similar concepts. OBJECTIVES: Given this, the aim of this article is to analyze the different aspects of the various hemoadsorption products offered on the market today and to take a critical look at the available evidence. METHODS: Technical features, application-specific characteristics, and the existing evidence of the adsorption technologies CytoSorb® (CytoSorbents(TM) Inc., Monmouth Junction, NJ, USA), Jafron® HA series (Jafron Biomedical Co., Guangdong, China), and Biosky® MG series (Biosun® Medical Technology Co., Foshan City, Guangdong Province, China) were analyzed. The purely substance-specific methods for endotoxin elimination only (Toraymyxin®, Alteco®) were not considered. RESULTS: A comprehensive analysis of these criteria reveals that there are considerable differences between the various available technologies in terms of materials used, adsorption characteristics, application, and available data on safety and clinical experience. Furthermore, it becomes clear that not only the efficacy of blood purification technologies should be considered in terms of an effect–price–performance ratio, but that in particular the safety of the individual technologies is of crucial importance. DISCUSSION: Among the technologies analyzed, CytoSorb currently represents the most investigated and clinically established procedure. Furthermore, it should be noted that clinical results, but particularly safety-relevant aspects, are not transferable between the products due to technically different procedures. Springer Medizin 2020-06-24 2021 /pmc/articles/PMC8159789/ /pubmed/32583037 http://dx.doi.org/10.1007/s00063-020-00702-2 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by/4.0/Open Access. Dieser Artikel wird unter der Creative Commons Namensnennung 4.0 International Lizenz veröffentlicht, welche die Nutzung, Vervielfältigung, Bearbeitung, Verbreitung und Wiedergabe in jeglichem Medium und Format erlaubt, sofern Sie den/die ursprünglichen Autor(en) und die Quelle ordnungsgemäß nennen, einen Link zur Creative Commons Lizenz beifügen und angeben, ob Änderungen vorgenommen wurden. Die in diesem Artikel enthaltenen Bilder und sonstiges Drittmaterial unterliegen ebenfalls der genannten Creative Commons Lizenz, sofern sich aus der Abbildungslegende nichts anderes ergibt. Sofern das betreffende Material nicht unter der genannten Creative Commons Lizenz steht und die betreffende Handlung nicht nach gesetzlichen Vorschriften erlaubt ist, ist für die oben aufgeführten Weiterverwendungen des Materials die Einwilligung des jeweiligen Rechteinhabers einzuholen. Weitere Details zur Lizenz entnehmen Sie bitte der Lizenzinformation auf http://creativecommons.org/licenses/by/4.0/deed.de (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Übersichten Krenn, C. G. Steltzer, H. Hämoadsorption zur Blutreinigung – Unvergleichbarkeit der klinisch angebotenen Verfahren |
title | Hämoadsorption zur Blutreinigung – Unvergleichbarkeit der klinisch angebotenen Verfahren |
title_full | Hämoadsorption zur Blutreinigung – Unvergleichbarkeit der klinisch angebotenen Verfahren |
title_fullStr | Hämoadsorption zur Blutreinigung – Unvergleichbarkeit der klinisch angebotenen Verfahren |
title_full_unstemmed | Hämoadsorption zur Blutreinigung – Unvergleichbarkeit der klinisch angebotenen Verfahren |
title_short | Hämoadsorption zur Blutreinigung – Unvergleichbarkeit der klinisch angebotenen Verfahren |
title_sort | hämoadsorption zur blutreinigung – unvergleichbarkeit der klinisch angebotenen verfahren |
topic | Übersichten |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8159789/ https://www.ncbi.nlm.nih.gov/pubmed/32583037 http://dx.doi.org/10.1007/s00063-020-00702-2 |
work_keys_str_mv | AT krenncg hamoadsorptionzurblutreinigungunvergleichbarkeitderklinischangebotenenverfahren AT steltzerh hamoadsorptionzurblutreinigungunvergleichbarkeitderklinischangebotenenverfahren |